At a glance
- Originator GlaxoSmithKline
- Class Small molecules
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 30 Aug 1999 Discontinued-I for Chronic obstructive pulmonary disease in USA (PO)
- 30 Aug 1999 Discontinued-Preclinical for Chronic obstructive pulmonary disease in Europe (PO)
- 16 Mar 1999 Phase-I clinical trials for Chronic obstructive pulmonary disease in USA (PO)